The abstract is read at the publisher; the summary is JClub's.
Platelet VEGFR3 deficiency enhances platelet activation, aggregation, secretion, cytoskeletal remodeling, thrombosis, and myocardial injury, linked to reduced VEGFR3 expression in myocardial infarction patients.
- Why it matters: VEGFR3 is known for lymphangiogenesis, but its intrinsic role in platelet activation and thrombotic outcomes was unclear, limiting therapeutic targeting in thrombotic disorders.
- What they did: PF4-Cre conditional deletion and pharmacological inhibition were combined with biochemical assays to test VEGFR3’s control of p190A, RhoA activation, and Ezrin/Radixin/Moesin phosphorylation.
- The result: VEGFR3 interacts with p190A to limit RhoA signaling and Ezrin/Radixin/Moesin phosphorylation, and in myocardial infarction, lower platelet VEGFR3 expression associates with higher platelet reactivity and more severe coronary lesions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.